|
Company:
|
CARISMA THERAPEUTICS INC. (CARM)
|
|
Form Type:
|
8-K
|
|
Filing Date:
|
2/25/2022
|
|
CIK:
|
0001485003
|
|
Address:
|
3675 MARKET STREET
SUITE 200
|
|
City, State, Zip:
|
PHILADELPHIA, Pennsylvania 19104
|
|
Telephone:
|
(267) 491-6422
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$5.18
|
Change:
0.38 (7.92%)
|
Trade Time:
May 26
|
Market Cap:
$208.52M
|
|
|
|
|
|
|
Description of Business
|
|
We are a late-stage clinical company that previously focused on advancing
targeted fusion protein therapeutics ("TFPTs") for the treatment of patients
with cancer.
Our most advanced product candidate, Vicineum, also known as VB4-845, is a
locally administered targeted fusion protein composed of an anti-epithelial cell
adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of
Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer
("NMIBC").
On July 15, 2022, we made the strategic decision to voluntarily pause further
development of Vicineum in the United States.
|
|
|
|